Pantera Minerals Limited High-Grade Antimony to 3.9% Sb and Extensive Soil Anomalies Confirm Priority Drill Targets

Sydney, Australia (ABN Newswire) - Pantera Minerals Limited (ASX:PFE) (OTCMKTS:PTMLF) provided an exploration update on its 100% Gillham project, covering ~5,000 acres in southwest Arkansas, USA. Results from the first modern exploration program have identified significant antimony, silver, gold and base metal anomalism, supported by high-grade rock samples and historical workings, highlighting the potential for multiple mineralised zones and advancing priority drill targets at the Gillham Project (See figure 1*).

First modern exploration assays from the Gillham Project have delivered high-grade antimony and base metal results, validating the project's potential and accelerating progress toward a maiden drill program.

HIGHLIGHTS

First pass rock chip sampling confirms high-grade antimony and base metal mineralization across multiple prospects, confirming the project's exploration potential.

- Significant results include:

- 3.92 percent Sb, 0.47 percent Pb, 10.3g/t Ag (GR008)

- 1.1 percent Sb, 1.32 percent Pb, 6g/t Ag, (GR009)

- 1.59g/t Au (GR021)

- 0.47g/t Au (GR016)1.96 percent Cu, 1.465 percent Zn 0.29 percent Pb (GR019)

- 4.79 percent Pb, 0.22 percent Cu, 20.5g/t Ag (GR041)

- 0.85 percent Sb (GR001)

Soil sampling has defined strong antimony anomalism, with peak values of 2,660ppm and 1,205ppm Sb, highlighting the scale of the mineralized system.

Coincident soil and rock sampling anomalies support the presence of multiple vein systems within the project area.

Two standout coherent coincident Sb-As-Zn-Pb anomalies (~500m strike) present as high priority drill targets.

Barnaby Egerton-Warburton, Executive Chairman and CEO, commented:

"These initial results provide highly encouraging validation of the Gillham Project, with high-grade antimony in rock chips up to 3.92 percent Sb directly associated with exceptional soil anomalies, up to 2,660ppm Sb. These results define coherent and compelling drill targets with the scale and continuity of the geochemical footprints supporting the presence of a potentially significant underlying mineralised system.

Importantly, previously unrecognised gold anomalism identified at West Gillham highlights the broader fertility of the system providing additional upside potential.

With multiple high-confidence targets now defined across a meaningful strike extent, we are advancing rapidly toward a maiden drilling program, which we expect will be a key value inflection point for the Company."

RECONNAISSANCE ROCK SAMPLING

Results have been received for the 46 rock chip samples (GR001-GR046) collected across the Gillham project area from old workings, mine dumps, sub crop and outcrop.

This represents the first ever modern exploration program undertaken at Gillham, confirming the historical results and validating the prospectivity of the project area.

Importantly, no drilling has been conducted across the Gillham project, highlighting the significant exploration upside and potential for new discoveries.

Stewart Prospect:

Historical records indicate the Stewart Mine produced ~1,000 tonnes of Stibnite, highlighting the prospect's established antimony endowment (Figures 1 & 4*).

Recent sampling has further validated and upgraded the prospect, returning high-grade results up to 3.92 percent Sb and +1.1 percent Sb, confirming strong antimony mineralisation and ranking it as a priority drill target.

Significant Results included:

- 3.92 percent Sb, 10.3g/t Ag, 0.47 percent Pb, (GR008)
- 1.1 percent Sb, 6 g/t Ag, 1.32 percent Pb, (GR009)

Davis Mine

The Davis Mine represents the largest historical operation within the Gillham Project area, with extensive underground development and favorable geological structures (Figure 5*).

Mineralisation is associated with structurally control zones within shale and siltstone units, with deformation along northeast-trending faults supporting fluid flow and metal deposition.

Recent rock-chip sampling has confirmed significant base metal and silver mineralisation, reinforcing the prospectivity of the area and its potential for follow-up drilling.

The two main shafts at Davis dip steeply to the to the north, with host units comprising shales and black siltstones dipping approximately 40 degrees to 60 degrees north.

Structural deformation along bedding planes and northeast-trending faults is evident at the shaft collars, with the overall strike of units and the vicinity estimated at approximately 070 degrees (ENE).

Significant results included:

- 1.96 percent Cu, 1.465 percent Zn 0.29 percent Pb (GR019)
- 4.79 percent Pb, 0.22 percent Cu, 20.5 g/t Ag (GR041)
- 0.31 percent Cu, 0.98 percent Zn (GR017)

New Prospect Areas

Multiple new prospect areas have been identified, reinforcing Gillham's potential to host district-scale polymetallic mineralised systems. Key areas include:

Andrews Gold Prospect:

The Andrews gold prospect is located approximately 2km west of the Davis Mine along a similar east-west structural trend and represents a newly recognised target not identified in historical records (Figure 5*).

Reconnaissance mapping identified several shallow historical diggings (~1-2m deep) with mineralised quartz mullock exhibiting iron staining, fine sulphides and evidence of sulphide depletion, supporting the presence of a prospective mineralised system.

Significant results included:

- 1.59 g/t Gold (GR021)
- 0.47 g/t Gold (GR016)

South-east Davis:

A series of historical diggings were identified ~400m to the ESE of the Davis Mine. Where four rock samples were collected from shaft walls and nearby outcrop (Figure 5*).

Three of the four samples returned anomalous gold mineralisation, highlighting the potential to extend mineralisation within the Davis area.

Anomalous gold values included:

- 0.16g/t gold (GR037)
- 0.13 g/t gold (GR036)

Antimony Bluff:

Several historic mine shafts have been identified at the Antimony Bluff mine site, highlighting established mineralisation within a favourable geological setting.

The local geology comprises shale unit dipping at ~55 degrees to the North, with a sandstone horizon forming the hanging wall. Mineralised quartz veins are interpreted to occur along the footwall contact and follow consistent east-west structural trends, in line with the broader project geology.

Significant results included:

- 0.85 percent Sb (GR001)
SOIL SAMPLING

Pantera Minerals completed first pass soil sampling program across five priority target areas, defined through detailed geological and structural interpretation.

A total of 1,411 soil samples were collected on a 100 x 50m grid with soil material taken from 20-30cm depth and sieved to -2mm to obtain a 300-500 gram sample.

Peak soil results returned 2,660ppm Antimony (Sb), 680ppm Zinc (Zn) and 1,245ppm Lead (Pb) highlighting strong multi-element anomalism across the project.

The sampling program in the Eastern License has defined two distinct and coherent antimony anomalies (~400m and ~500m strike) along the Stewart/May trend, supported by coincident arsenic (+30ppm), Lead (+80ppm) and Zinc (+80ppm) anomalism.
The two anomalies follow the interpreted E-W trend and extend ~400m and ~500m in strike length, respectively. The western anomaly is supported by coincident high-grade rockchips with results up to 3.92 percent Sb and 1.1 percent Sb. Both anomalies are linked by a broader +1ppm Sb trend extending over 2,000m along strike, highlighting the scale and continuity of the mineralised system.

The eastern high-grade anomaly remains untested by mapping or rock sampling and represents a high-priority follow-up target.

In the Western Gillham Project, the historic Davis Mine is defined by a +80ppm lead anomaly with coincident +80ppm zinc and minor arsenic anomalism, while the newly identified South-East Davis gold prospect coincides with a +30-ppm arsenic soil anomaly, warranting follow-up field investigations across additional unexplored arsenic anomalies in the area.

The company is highly encouraged by the results of the first-phase geochemical sampling program, which has successfully defined multiple high-priority targets and supports ongoing advancement toward drilling. Further exploration activities are planned to refine and expand these targets.

Pantera is executing a U.S.-focused critical minerals strategy, advancing Gillham toward drilling while continuing to assess additional high-impact opportunities to build a diversified portfolio of strategically positioned assets.

Next Steps:

- Infill soil sampling and targeted rock sampling to refine anomalies.

- Detailed mapping and advancement of drill planning

- Assessment of additional U.S. - based mineral project opportunities to complement the Company's strategy

*To view tables and figures, please visit:
https://abnnewswire.net/lnk/649H8FB0

About Pantera Minerals Limited:Pantera Minerals Limited (ASX:PFE) (OTCMKTS:PTLMF) is a forward-looking critical minerals exploration and development company focused on advancing projects in critical minerals across the United States with a particular focus on its projects located in Southwest Arkansas.With newly acquired mineral leases covering historically productive ground, Pantera is positioned to re-establish exploration in a district that has seen no systematic modern work for nearly a century.The Company is committed to leveraging modern exploration methods including geochemistry, geophysics, and advanced modelling to unlock value in regions historically mined for critical minerals, which are recognised by the U.S. government as essential to supply chain security.



Source:
Pantera Minerals Limited



Contact:
Barnaby Egerton-Warburton
Executive Chairman and CEO
E: bew@panterali.com
P: +61 (0) 437 291 155

Jane Morgan
Investor Relations
E: jm@janemorganmanagement.com.au
P: +61 (0) 405 555 618

News Provided by ABN Newswire via QuoteMedia

PFE
The Conversation (0)
Arvinas and Pfizer Announce Upcoming Vepdegestrant  Poster Presentations at the 2023 European Society for Medical Oncology  Breast Cancer Annual Congress

Arvinas and Pfizer Announce Upcoming Vepdegestrant Poster Presentations at the 2023 European Society for Medical Oncology Breast Cancer Annual Congress

Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated data related to vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress. Vepdegestrant is a novel investigational PROTAC ® estrogen receptor... Keep Reading...
Pfizer Reports First-Quarter 2023 Results

Pfizer Reports First-Quarter 2023 Results

First-Quarter 2023 Revenues of $18.3 Billion Expected Decline in Comirnaty (1) Revenue Drove 26% Operational Decrease in First-Quarter 2023 Revenues First-Quarter 2023 Revenues from Comirnaty (1) and Paxlovid of $7.1 Billion Excluding Contributions from Comirnaty (1) and Paxlovid, Revenues Grew... Keep Reading...
XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki... Keep Reading...
U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

U.S. FDA Approves PREVNAR 20®, Pfizer's 20-valent Pneumococcal Conjugate Vaccine for Infants and Children

PREVNAR 20 offers the broadest serotype coverage of any pediatric pneumococcal conjugate vaccine, helping to protect against all 20 serotypes contained in the vaccine PREVNAR 20 builds on PREVNAR 13 ® and includes seven additional serotypes shown to be associated with antibiotic resistance,... Keep Reading...
Pfizer Declares Second-Quarter 2023 Dividend

Pfizer Declares Second-Quarter 2023 Dividend

Board of Directors approves quarterly cash dividend of $0.41 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 second-quarter 2023 dividend on the company's common stock, payable June 9, 2023, to holders of the Common Stock of record at the close of... Keep Reading...
InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Human Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsInMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the... Keep Reading...
SVN-114 selected as the lead candidate for PTSD discovery programme

SVN-114 selected as the lead candidate for PTSD discovery programme

Novel compound from patent-pending SVN-SDN-14 series targeting a major global mental health disorder

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel small-molecule therapeutics for high-burden central nervous system ("CNS") disorders, announces the selection of SVN-114 as the lead candidate from the Company's proprietary SVN-SDN-14 discovery... Keep Reading...
InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Advancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused... Keep Reading...
InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned... Keep Reading...
Box of Moderna COVID-19 vaccine vials with red caps and labels.

Moderna to Pay US$950 Million to Settle COVID-19 Vaccine Patent Dispute

Moderna (NASDAQ:MRNA) has agreed to pay US$950 million to resolve a long-running patent dispute tied to the technology used in its COVID-19 vaccine.The pharmaceuticals giant announced it has reached a global settlement with Arbutus Biopharma (NASDAQ:ABUS) and Genevant Sciences GmbH over claims... Keep Reading...
Scientists examining a sample under a microscope in a lab setting.

Gilead to Acquire Arcellx in US$7.8 Billion Bet on Cancer Therapy

Gilead Sciences (NASDAQ:GILD) announced plans to acquire cancer immunotherapy partner Arcellx (NASDAQ:ACLX) in a deal worth up to US$7.8 billion, moving to take full control of their jointly developed multiple myeloma therapy anito-cel as it seeks to expand its oncology pipeline.The agreement,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News